Assembly Biosciences Inc Earnings
The next earnings date for Assembly Biosciences Inc has not yet been scheduled.
Analyst Estimates of Assembly Biosciences Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Assembly Biosciences Inc Earnings: Historical
| 08/13/2026 | After Market | $-0.20 | 71.43% |
| 05/07/2026 | After Market | $-0.54 | 15.63% |
| 11/10/2025 | After Market | $-0.72 | -10.77% |
| 08/06/2025 | After Market | $-1.33 | 23.12% |
| 05/08/2025 | After Market | $-1.17 | 26.88% |
| 03/26/2025 | Before Market | $-1.57 | 10.29% |
| 11/07/2024 | After Market | $-1.51 | 18.38% |
| 08/08/2024 | After Market | $-1.98 | 11.21% |
| 05/08/2024 | After Market | $-1.66 | 48.61% |
| 01/31/2024 | After Market | $-2.15 | 25.35% |
More About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
“Assembly Biosciences Inc Earnings” Can Refer to the Assembly Biosciences Inc Earnings Date
Some people say “Assembly Biosciences Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Assembly Biosciences Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Assembly Biosciences Inc Stock on the Earnings Date
If you own Assembly Biosciences Inc stock (ASMB) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Assembly Biosciences Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Assembly Biosciences Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Assembly Biosciences Inc Earnings
You can contact us any time if you would like to ask questions about Assembly Biosciences Inc earnings or anything else related to the stock market.